γ-分泌酶抑制剂在阿尔茨海默病患者随机研究中的作用。

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

作者信息

Siemers E R, Quinn J F, Kaye J, Farlow M R, Porsteinsson A, Tariot P, Zoulnouni P, Galvin J E, Holtzman D M, Knopman D S, Satterwhite J, Gonzales C, Dean R A, May P C

机构信息

Eli Lilly and Company, Indianapolis, IN 46085, USA.

出版信息

Neurology. 2006 Feb 28;66(4):602-4. doi: 10.1212/01.WNL.0000198762.41312.E1.

DOI:10.1212/01.WNL.0000198762.41312.E1

PMID:16505324

Abstract

LY450139 dihydrate, a gamma-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Abeta(1-40) in plasma decreased by 38.2%; in CSF, Abeta(1-40) decreased by 4.42 +/- 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Abeta concentrations and a measurable decrease in CSF Abeta.

摘要

γ-分泌酶抑制剂LY450139二水合物在一项针对70名阿尔茨海默病患者的随机对照试验中进行了研究。受试者先服用30毫克，持续1周，随后服用40毫克，持续5周。治疗耐受性良好。血浆中的β淀粉样蛋白1-40（Aβ(1-40)）降低了38.2%；脑脊液中的Aβ(1-40)降低了4.42±9.55%（p值无统计学意义）。更高的药物剂量可能会使血浆Aβ浓度进一步降低，并使脑脊液Aβ出现可测量的下降。